CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) – Equities researchers at SVB Leerink lowered their Q2 2022 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, May 9th. SVB Leerink analyst R. Bienkowski now anticipates that the company will post earnings per share of ($2.22) for the quarter, down from their prior forecast of ($1.76). SVB Leerink currently has a “Outperform” rating and a $120.00 target price on the stock. SVB Leerink also issued estimates for CRISPR Therapeutics’ Q3 2022 earnings at ($2.21) EPS, Q4 2022 earnings at ($2.26) EPS, FY2022 earnings at ($9.16) EPS and FY2023 earnings at ($8.94) EPS.
A number of other analysts have also issued reports on the company. Credit Suisse Group started coverage on CRISPR Therapeutics in a research note on Thursday, April 28th. They set a “neutral” rating and a $78.00 price objective on the stock. Barclays reduced their price objective on shares of CRISPR Therapeutics from $107.00 to $99.00 in a research note on Tuesday. StockNews.com started coverage on shares of CRISPR Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Truist Financial reissued a “buy” rating and set a $220.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, February 16th. Finally, Brookline Capital Management restated a “buy” rating and issued a $143.00 target price on shares of CRISPR Therapeutics in a research note on Monday, February 14th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $122.36.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($1.94) by ($0.38). The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $2.45 million. CRISPR Therapeutics had a return on equity of 16.21% and a net margin of 41.28%. The firm’s revenue was up 74.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.51) EPS.
Several hedge funds have recently added to or reduced their stakes in CRSP. Sumitomo Mitsui Trust Holdings Inc. purchased a new position in CRISPR Therapeutics in the 1st quarter worth approximately $289,982,000. Nikko Asset Management Americas Inc. raised its holdings in CRISPR Therapeutics by 7.0% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,619,747 shares of the company’s stock valued at $291,044,000 after buying an additional 300,276 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in CRISPR Therapeutics by 42.1% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,316,123 shares of the company’s stock valued at $99,736,000 after buying an additional 390,209 shares during the period. BlackRock Inc. grew its holdings in CRISPR Therapeutics by 12.6% in the 4th quarter. BlackRock Inc. now owns 1,271,528 shares of the company’s stock worth $96,358,000 after acquiring an additional 142,244 shares during the last quarter. Finally, Bellevue Group AG increased its position in shares of CRISPR Therapeutics by 0.8% in the third quarter. Bellevue Group AG now owns 974,684 shares of the company’s stock valued at $109,096,000 after acquiring an additional 7,800 shares during the period. 56.12% of the stock is currently owned by institutional investors.
CRISPR Therapeutics Company Profile (Get Rating)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.